JPWO2022102768A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022102768A5 JPWO2022102768A5 JP2022502914A JP2022502914A JPWO2022102768A5 JP WO2022102768 A5 JPWO2022102768 A5 JP WO2022102768A5 JP 2022502914 A JP2022502914 A JP 2022502914A JP 2022502914 A JP2022502914 A JP 2022502914A JP WO2022102768 A5 JPWO2022102768 A5 JP WO2022102768A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- tspan8
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 184
- 150000001413 amino acids Chemical class 0.000 claims description 156
- 229920001184 polypeptide Polymers 0.000 claims description 78
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 78
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 78
- 239000012634 fragment Substances 0.000 claims description 63
- 239000002157 polynucleotide Substances 0.000 claims description 47
- 102000040430 polynucleotide Human genes 0.000 claims description 47
- 108091033319 polynucleotide Proteins 0.000 claims description 47
- 239000002773 nucleotide Substances 0.000 claims description 30
- 125000003729 nucleotide group Chemical group 0.000 claims description 30
- 230000035772 mutation Effects 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 21
- 101000847107 Homo sapiens Tetraspanin-8 Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 102100032802 Tetraspanin-8 Human genes 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000004481 post-translational protein modification Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 230000004927 fusion Effects 0.000 description 6
- 102000054699 human TSPAN8 Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022036009A JP7802282B2 (ja) | 2020-11-16 | 2022-03-09 | 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020189988 | 2020-11-16 | ||
| JP2020189988 | 2020-11-16 | ||
| PCT/JP2021/041839 WO2022102768A1 (ja) | 2020-11-16 | 2021-11-15 | 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036009A Division JP7802282B2 (ja) | 2020-11-16 | 2022-03-09 | 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022102768A1 JPWO2022102768A1 (https=) | 2022-05-19 |
| JP7078237B1 JP7078237B1 (ja) | 2022-05-31 |
| JPWO2022102768A5 true JPWO2022102768A5 (https=) | 2022-10-24 |
Family
ID=81601338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502914A Active JP7078237B1 (ja) | 2020-11-16 | 2021-11-15 | 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体 |
| JP2022036009A Active JP7802282B2 (ja) | 2020-11-16 | 2022-03-09 | 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036009A Active JP7802282B2 (ja) | 2020-11-16 | 2022-03-09 | 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11897954B2 (https=) |
| EP (1) | EP4245855A4 (https=) |
| JP (2) | JP7078237B1 (https=) |
| KR (1) | KR20230108288A (https=) |
| CN (1) | CN116635071A (https=) |
| AR (1) | AR124063A1 (https=) |
| AU (1) | AU2021378575A1 (https=) |
| CA (1) | CA3200860A1 (https=) |
| CL (1) | CL2023001392A1 (https=) |
| CO (1) | CO2023007734A2 (https=) |
| CR (1) | CR20230244A (https=) |
| DO (1) | DOP2023000096A (https=) |
| EC (1) | ECSP23034684A (https=) |
| IL (1) | IL302544A (https=) |
| JO (1) | JOP20230106A1 (https=) |
| MX (1) | MX2023005346A (https=) |
| PE (1) | PE20240224A1 (https=) |
| TW (1) | TW202229353A (https=) |
| WO (1) | WO2022102768A1 (https=) |
| ZA (1) | ZA202305642B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116635071A (zh) * | 2020-11-16 | 2023-08-22 | 安斯泰来制药株式会社 | 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体 |
| JP2025087939A (ja) * | 2022-04-13 | 2025-06-11 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用 |
| CA3256973A1 (en) * | 2022-05-12 | 2025-06-17 | Astellas Pharma Inc. | MULTI-SPECIFIC ANTI-CD3 AND ANTI-CD3 ANTIBODY |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| US9040671B2 (en) | 2010-07-23 | 2015-05-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for cancer management targeting Co-029 |
| KR101238594B1 (ko) | 2010-07-27 | 2013-02-28 | 엘지이노텍 주식회사 | 스티어링 시스템의 토크 센서 |
| AU2013315128B2 (en) * | 2012-09-14 | 2019-01-03 | Memorial Sloan-Kettering Cancer Center | Genes associated with dasatinib sensitivity |
| US9850303B2 (en) | 2013-03-15 | 2017-12-26 | The Translational Genomics Research Institute | Hybridoma clones and monoclonal antibodies to tetraspanin 8 |
| KR101906558B1 (ko) | 2014-02-28 | 2018-10-11 | (재) 스크립스코리아항체연구원 | Tspan8에 특이적인 신규 항체 및 이의 용도 |
| KR20150130115A (ko) | 2014-05-13 | 2015-11-23 | 연세대학교 산학협력단 | 상온 대기압 플라즈마를 이용한 치은 섬유아세포의 세포활성도 촉진 방법 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| JP7072792B2 (ja) | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
| CN116635071A (zh) * | 2020-11-16 | 2023-08-22 | 安斯泰来制药株式会社 | 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体 |
-
2021
- 2021-11-15 CN CN202180076884.7A patent/CN116635071A/zh active Pending
- 2021-11-15 WO PCT/JP2021/041839 patent/WO2022102768A1/ja not_active Ceased
- 2021-11-15 US US17/639,783 patent/US11897954B2/en active Active
- 2021-11-15 JP JP2022502914A patent/JP7078237B1/ja active Active
- 2021-11-15 CA CA3200860A patent/CA3200860A1/en active Pending
- 2021-11-15 AU AU2021378575A patent/AU2021378575A1/en not_active Abandoned
- 2021-11-15 EP EP21892013.0A patent/EP4245855A4/en active Pending
- 2021-11-15 PE PE2023001609A patent/PE20240224A1/es unknown
- 2021-11-15 IL IL302544A patent/IL302544A/en unknown
- 2021-11-15 TW TW110142388A patent/TW202229353A/zh unknown
- 2021-11-15 MX MX2023005346A patent/MX2023005346A/es unknown
- 2021-11-15 AR ARP210103152A patent/AR124063A1/es not_active Application Discontinuation
- 2021-11-15 CR CR20230244A patent/CR20230244A/es unknown
- 2021-11-15 KR KR1020237019446A patent/KR20230108288A/ko active Pending
-
2022
- 2022-03-09 JP JP2022036009A patent/JP7802282B2/ja active Active
-
2023
- 2023-05-11 EC ECSENADI202334684A patent/ECSP23034684A/es unknown
- 2023-05-15 CL CL2023001392A patent/CL2023001392A1/es unknown
- 2023-05-15 DO DO2023000096A patent/DOP2023000096A/es unknown
- 2023-05-15 JO JOJO/P/2023/0106A patent/JOP20230106A1/ar unknown
- 2023-05-25 ZA ZA2023/05642A patent/ZA202305642B/en unknown
- 2023-06-14 CO CONC2023/0007734A patent/CO2023007734A2/es unknown
- 2023-12-26 US US18/396,461 patent/US12304951B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brinkmann et al. | The making of bispecific antibodies | |
| AU2022218544B2 (en) | Hetero-dimeric multi-specific antibody format | |
| JP2021098732A5 (https=) | ||
| JP2022551969A5 (https=) | ||
| Krah et al. | Engineering bispecific antibodies with defined chain pairing | |
| Marvin et al. | Recombinant approaches to IgG‐like bispecific antibodies | |
| CA2963615C (en) | ANTIBODIES WITH A DOMAIN EXCHANGE | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021098733A5 (https=) | ||
| IL272747B2 (en) | Bispecific antibodies 1 + 2 | |
| JPWO2022102768A5 (https=) | ||
| JP2018537966A5 (https=) | ||
| HUE028230T2 (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| RU2019108429A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2018522541A5 (https=) | ||
| JP2018526981A5 (https=) | ||
| JP2024537779A5 (https=) | ||
| JP2021533159A5 (https=) | ||
| JP2021507698A5 (https=) | ||
| JP2024534545A5 (https=) | ||
| JP2024501403A5 (https=) | ||
| JP2023548529A5 (https=) | ||
| JPWO2021241616A5 (https=) | ||
| JP7657591B2 (ja) | 二重特異性抗原結合コンストラクト | |
| JP2023511376A5 (https=) |